Illumina, Inc. (ILMN): Price and Financial Metrics

Illumina, Inc. (ILMN)

Today's Latest Price: $309.69 USD

0.00 (0.00%)

Updated Oct 29 9:09am

Add ILMN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ILMN Stock Summary

  • With a market capitalization of $45,214,740,000, Illumina Inc has a greater market value than 95.78% of US stocks.
  • The price/operating cash flow metric for Illumina Inc is higher than 90.2% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 13.49, Illumina Inc has a higher such ratio than 89.43% of stocks in our set.
  • Stocks that are quantitatively similar to ILMN, based on their financial statements, market capitalization, and price volatility, are NTES, ADI, VMW, ATVI, and SPOT.
  • Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to

ILMN Stock Price Chart Interactive Chart >

Price chart for ILMN

ILMN Price/Volume Stats

Current price $309.69 52-week high $404.20
Prev. close $309.69 52-week low $196.78
Day low $309.69 Volume 1,197
Day high $309.69 Avg. volume 1,277,464
50-day MA $326.88 Dividend yield N/A
200-day MA $324.30 Market Cap 45.21B

Illumina, Inc. (ILMN) Company Bio

Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$309.69$147.37 -52%

Below please find a table outlining a discounted cash flow forecast for ILMN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Illumina Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Illumina Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 21.05; that's higher than 86.41% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 12.64% of the free cash flow producing stocks we're observing.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.87% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try CPIX, JNJ, LMAT, ZTS, and HAPP.

ILMN Latest News Stream

Event/Time News Detail
Loading, please wait...

ILMN Latest Social Stream

Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Top Analyst Upgrades and Downgrades: Delta, Hasbro, Illumina, Lululemon, Micron, Nike, Penn National, Shopify, Southwest, Starbucks, Zynga and More

No summary available.

24/7 Wall street | September 30, 2020

Gene Expression Market Reflect a Holistic Expansion With Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Bio-Rad Laboratories, OriGene Technologies, Illumina, Inc., QIAGEN

A report by The Insight Partner's on the Gene Expression Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the

OpenPR | September 29, 2020

Global Function Driven Metagenomics Market Projected To Show Strong Growth By 2026 | |Danaher; Merck KGaA; Illumina, Inc.; Thermo Fisher Scientific Inc.; QIAGEN; F. Hoffmann-La Roche Ltd; Novogene Corporation

The numerous recent developments, products launches, research, joint ventures, mergers and acquisitions in the Function Driven Metagenomics market which is changing the face healthcare industry.We at Data Bridge Market Research understand what is important in the Function Driven

OpenPR | September 29, 2020

Week In Review: Illumina Pays $8 Billion To Acquire GRAIL, An Early-Stage Cancer Testing Company

Deals and Financings Illumina (ILMN) will acquire GRAIL (GRAL), an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock (see story). In 2017, GRAIL bought Cirina, a Hong Kong-San Francisco liquid biopsy company cofounded by Dr. Dennis Lo,...

ChinaBio Today on Seeking Alpha | September 28, 2020

Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details

Business Wire | September 28, 2020

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo 1.37%
3-mo -18.96%
6-mo 1.25%
1-year 4.45%
3-year 51.95%
5-year 116.14%
YTD -6.65%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%
2015 3.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8081 seconds.